Michael C. Cox

6.4k total citations · 2 hit papers
53 papers, 2.7k citations indexed

About

Michael C. Cox is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Neurology. According to data from OpenAlex, Michael C. Cox has authored 53 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 14 papers in Neurology. Recurrent topics in Michael C. Cox's work include Lung Cancer Treatments and Mutations (13 papers), Neuroblastoma Research and Treatments (13 papers) and Glioma Diagnosis and Treatment (9 papers). Michael C. Cox is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Neuroblastoma Research and Treatments (13 papers) and Glioma Diagnosis and Treatment (9 papers). Michael C. Cox collaborates with scholars based in United States, Germany and Australia. Michael C. Cox's co-authors include William D. Figg, Alex Sparreboom, Milin Acharya, Alberto S. Pappo, Ramamoorthy Nagasubramanian, Steven G. DuBois, Theodore W. Laetsch, C. O. Qualset, Brian Turpin and D. W. Rains and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Michael C. Cox

52 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal

2010 558 citations Michael C. Cox et al. Journal of Clinical Oncology profile →
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study

2018 378 citations Theodore W. Laetsch, Steven G. DuBois et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael C. Cox United States	23	746	710	576	545	492	53	2.7k
Ron Epelbaum Israel	40	1.0k 1.4×	1.9k 2.7×	144 0.3×	1.6k 2.9×	854 1.7×	114	4.8k
K. Hemminki Sweden	30	349 0.5×	682 1.0×	119 0.2×	525 1.0×	861 1.8×	89	2.8k
Janardan D. Khandekar United States	24	481 0.6×	1.3k 1.8×	124 0.2×	397 0.7×	535 1.1×	78	3.3k
B. J. Kennedy United States	38	792 1.1×	1.4k 2.0×	122 0.2×	436 0.8×	784 1.6×	135	4.1k
Michael Huncharek United States	32	964 1.3×	810 1.1×	149 0.3×	289 0.5×	468 1.0×	74	3.1k
Deqing Pei United States	40	467 0.6×	1.0k 1.4×	57 0.1×	360 0.7×	1.5k 3.1×	85	5.8k
Ramzi Dagher United States	24	656 0.9×	848 1.2×	78 0.1×	290 0.5×	982 2.0×	39	2.6k
Shailendra Verma Canada	33	1.3k 1.7×	2.7k 3.7×	219 0.4×	261 0.5×	781 1.6×	177	4.8k
Masashi Ando Japan	31	954 1.3×	2.0k 2.9×	112 0.2×	378 0.7×	688 1.4×	206	3.6k
Bridget A. Robinson New Zealand	37	697 0.9×	2.0k 2.8×	113 0.2×	615 1.1×	1.3k 2.7×	140	4.4k

Countries citing papers authored by Michael C. Cox

Since Specialization

Citations

This map shows the geographic impact of Michael C. Cox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael C. Cox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael C. Cox more than expected).

Fields of papers citing papers by Michael C. Cox

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael C. Cox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael C. Cox. The network helps show where Michael C. Cox may publish in the future.

Co-authorship network of co-authors of Michael C. Cox

This figure shows the co-authorship network connecting the top 25 collaborators of Michael C. Cox. A scholar is included among the top collaborators of Michael C. Cox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael C. Cox. Michael C. Cox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lakhani, Nehal J., Timothy A. Yap, Afshin Dowlati, et al.. (2025). A phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of the first-in-class cyclin A/B RxL inhibitor CID-078, an orally bioavailable, cell-permeable macrocycle.. Journal of Clinical Oncology. 43(16_suppl).

Landi, Daniel, David S. Ziegler, Patricia Baxter, et al.. (2022). FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). TPS10062–TPS10062. 3 indexed citations

Jones, David, René Schmidt, Shivaram Avula, et al.. (2022). CTNI-30. LOGGIC/FIREFLY-2: A PHASE 3, RANDOMIZED TRIAL OF TOVORAFENIB VS. CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED LOW-GRADE GLIOMA HARBORING AN ACTIVATING RAF ALTERATION. Neuro-Oncology. 24(Supplement_7). vii77–vii78. 1 indexed citations

Hughes, Amy, Robert C. Shamberger, Suzanne Shusterman, et al.. (2019). A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma. Thyroid. 29(11). 1704–1707. 24 indexed citations

Tilburg, Cornelis M. van, Steven G. DuBois, Catherine M. Albert, et al.. (2019). Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.. Journal of Clinical Oncology. 37(15_suppl). 10010–10010. 12 indexed citations

Drilon, Alexander, Steven G. DuBois, Anna F. Farago, et al.. (2019). Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors.. Journal of Clinical Oncology. 37(15_suppl). 2006–2006. 55 indexed citations

Ziegler, David S., Marie Wong, Chelsea Mayoh, et al.. (2018). Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma. British Journal of Cancer. 119(6). 693–696. 81 indexed citations

McCarville, M. Beth, et al.. (2018). Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma. Pediatric Blood & Cancer. 65(10). e27271–e27271. 22 indexed citations

Hong, David S., Marcia S. Brose, Robert C. Doebele, et al.. (2015). Abstract PR13: Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions. Molecular Cancer Therapeutics. 14(12_Supplement_2). PR13–PR13. 12 indexed citations

10.

Denduluri, Neelima, James J. Lee, Janice M. Walshe, et al.. (2006). Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Investigational New Drugs. 25(1). 63–67. 38 indexed citations

11.

Cox, Michael C., et al.. (2005). Angiogenesis and prostate cancer: Important laboratory and clinical findings. Current Oncology Reports. 7(3). 215–219. 12 indexed citations

12.

Chen, Ming‐Hui, et al.. (2005). Prostate‐specific antigen velocity and survival for patients with hormone‐refractory metastatic prostate carcinoma. Cancer. 106(1). 63–67. 20 indexed citations

13.

D’Amico, Anthony V., Ming‐Hui Chen, Michael C. Cox, William L. Dahut, & William D. Figg. (2005). Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer. Urology. 66(3). 571–576. 12 indexed citations

14.

Figg, William D., Yinong Liu, Philip M. Arlen, et al.. (2005). A RANDOMIZED, PHASE II TRIAL OF KETOCONAZOLE PLUS ALENDRONATE VERSUS KETOCONAZOLE ALONE IN PATIENTS WITH ANDROGEN INDEPENDENT PROSTATE CANCER AND BONE METASTASES. The Journal of Urology. 173(3). 790–796. 56 indexed citations

15.

Cox, Michael C., et al.. (2005). Antiangiogenesis: A Possible Treatment Option for Prostate Cancer?. Clinical Genitourinary Cancer. 4(3). 197–202. 7 indexed citations

16.

Cox, Michael C., Charity D. Scripture, & William D. Figg. (2005). Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?. Expert Review of Anticancer Therapy. 5(4). 605–611. 24 indexed citations

17.

Figg, William D., Michael Franks, David Venzon, et al.. (2004). Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer. World Journal of Urology. 22(6). 425–430. 11 indexed citations

18.

Rudek, Michelle A., Kenneth S. Bauer, Richard M. Lush, et al.. (2003). Clinical Pharmacology of Flavopiridol following a 72-Hour Continuous Infusion. Annals of Pharmacotherapy. 37(10). 1369–1374. 36 indexed citations

19.

Arlen, Philip M., William D. Figg, James L. Gulley, et al.. (2002). National Cancer Institute Intramural Approach to Advanced Prostate Cancer. PubMed. 1(3). 153–162. 7 indexed citations

20.

Dingwall, Robert, et al.. (1978). Readings in the sociology of nursing. Nottingham Trent University's Institutional Repository (Nottingham Trent Repository). 108 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact